scorecardresearch
Follow Us:
Monday, May 23, 2022

Zydus Lifesciences launches drug for treating bad cholesterol

"With Bemdac we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c," Zydus Lifesciences Managing Director Sharvil Patel said.

By: PTI |
Updated: May 13, 2022 12:54:27 pm
Zydus said, 8 out of 10 Indians are dyslipidemic1 and 112 million adults suffer from high levels of LDL-c; 7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c.

Zydus Lifesciences on Friday said it has launched in India its Bempedoic acid drug under the Bemdac brand for treatment of uncontrolled levels of bad cholesterol.

Bemdac (Bempedoic acid) is a new class of drug which is orally administered and offers a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite lifestyle modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management, the company said in a regulatory filing.

“With Bemdac we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c,” Zydus Lifesciences Managing Director Sharvil Patel said.

Stating that Bemdac is an important addition to Zydus’ portfolio of medicines for managing dyslipidemia and cholesterol, Patel said the mission is to empower patients with a better quality of life through effective disease management and with Bemdac the company has taken a great leap ahead in this endeavour.

Best of Express Premium

ExplainSpeaking: Fisc in the time of monetary tighteningPremium
Delhi Confidential: Haryana CM Manohar Lal Khattar and his love for JapanesePremium
Nikhat Zareen: ‘People told my father that boxing was a men’s sportPremium
Remove harmonium from Golden Temple? Sikh music scholars strike differing...Premium

The company said LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like heart attack or stroke. Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases.

Citing various studies, Zydus said, 8 out of 10 Indians are dyslipidemic1 and 112 million adults suffer from high levels of LDL-c; 7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c.

Besides this, 5.4 million Indians are found to be intolerant to statin therapy, it added.

Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins. This is a huge unmet healthcare need which Bemdac addresses, Zydus claimed.

📣 The above article is for information purposes only and is not intended to be a substitute for professional medical advice. Always seek the guidance of your doctor or other qualified health professional for any questions you may have regarding your health or a medical condition.

For all the latest Lifestyle News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
Advertisement
Advertisement
Advertisement
Advertisement